Contract Sales Clause Samples

The Contract Sales clause defines the terms and conditions under which goods or services are sold under a contract. It typically outlines the scope of products or services covered, pricing arrangements, delivery schedules, and payment terms. For example, it may specify minimum purchase quantities, deadlines for placing orders, or procedures for handling returns. This clause ensures both parties have a clear understanding of their sales-related obligations, reducing the risk of disputes and providing a framework for managing the commercial relationship.
Contract Sales. The total number of RSUs which become vested based on the achievement of Contract Sales performance levels shall be equal to (x) the target number of RSUs specified above with respect to Contract Sales multiplied by (y) a relative weighting component equal to XX percent (XX%), multiplied by (z) the Achievement Percentage determined based upon the applicable Contract Sales Position for the Performance Period as follows, and rounded down to the nearest whole Share: Below Threshold Less than $XXM 0% Threshold $XXM 50% Target $XXM 100% Maximum $XXM 200%
View SourceView Similar (2)
Contract Sales. Primary Contact Email Primary Contact Phone Primary Contact Fax 1 0 Primary Contact Mobile 1 1 Secondary Contact Name Secondary Contact Title
View Source
Contract Sales. Contract sales commence with the Seller submitting a quotation or an offer to the Buyer. All quotations/offers submitted by the Seller are without obligation. Acceptance only results in an agreement if the Seller does not revoke the quotation/offer before or immediately after acceptance. Quotations/offers and acceptance thereof may be made in writing or orally.
View Source
Contract Sales. Sales Material and Information ----------------------------------------------- 4.1 The Company shall furnish, or shall cause to be furnished, to the Fund or its designee, the disclosure document and each piece of Contract sales material in which the Fund, the Adviser or the Underwriter is named, at least ten (10) Business Days prior to its use. No such material shall be used if the Fund or its designee object to such use within ten (10) Business Days after receipt of such material. 4.2 The Company shall not give any information or make any written representations or statements on behalf of the Fund or concerning the fund in connection with the sale of the Contracts other than the information or representations contained in the then current registration statement or prospectus for the Fund shares, as such registration statement and prospectus for the Fund shares may be amended or supplemented from time to time, or in reports or proxy statements for the Fund, or in Fund sales literature approved by the Fund or its designee or by the Underwriter, except with the permission of the Fund or the Underwriter or the designee of either. 4.3 The Fund, the Adviser, and the Underwriter understand and acknowledge that each Account is relying on Section 3(c)(1) of the 1940 Act to be excluded from the definition of investment company under the 1940 Act, and that the Contracts are relying on Regulation D for an exemption from registration under the 1933 Act. Accordingly, each of the Fund, the Adviser, and the Underwriter agree that it will not, orally or in the fund sales literature or otherwise in writing, give any information or make any representations concerning the Company, each Account, or the Contracts, without the prior written consent of the Company. 4.4 The Fund will provide to the Company at least one complete copy of all registration statements, prospectuses, statements of additional information, reports proxy statements, Fund sales literature, applications for exemptions, requests for no-action letters, and all amendments to any of the above, that relate to the Fund or its shares, contemporaneously with the filing of such document with the SEC or other regulatory authorities. 4.5 The Company will provide to the Fund at least one complete copy of all disclosure documents, reports, solicitations for voting instructions, and Contract sales material, applications for exemptions, requests for no action letters, and all amendments to any of the above, that relate to...
View Source
Contract Sales. The total number of RSUs which become vested based on the achievement of Contract Sales performance levels shall be equal to (x) the target number of RSUs specified above with respect to Contract Sales multiplied by (y) a relative weighting component equal to XX percent (XX%), multiplied by (z) the Achievement Percentage determined based upon the applicable Contract Sales Position for the Performance Period as follows, and rounded down to the nearest whole Share: Below Threshold Less than $XX M 0% Threshold $XX M 50% Target $XX M 100% Maximum $XX M 200% • Continued Employment or Service. In addition to the attainment of the Performance Conditions, the Participant must be an employee of or in service to the Company or the Company Group from the Date of Grant until the last day of the Performance Period, except to the extent otherwise provided in the Plan or the Agreement.
View Source

Related to Contract Sales

  • Contract Sales Price The total consideration provided for in the sales contract for the sale of a Property.

  • CONTRACT SALES REPORTING Contractor shall report total Contract sales quarterly to Enterprise Services, as set forth below. (a) Contract Sales Reporting System. Contractor shall report quarterly Contract sales in Enterprise Services’ Contract Sales Reporting System. Enterprise Services will provide Contractor with a login password and a vendor number. The password and vendor number will be provided to the Sales Reporting Representative(s) listed on Contractor’s Bidder Profile. (b) Data. Each sales report must identify every authorized Purchaser by name as it is known to Enterprise Services and its total combined sales amount invoiced during the reporting period (i.e., sales of an entire agency or political subdivision, not its individual subsections). The “Miscellaneous” option may be used only with prior approval by Enterprise Services. Upon request, Contractor shall provide contact information for all authorized Purchasers specified herein during the term of the Contract. If there are no Contract sales during the reporting period, Contractor must report zero sales. (c) Due dates for Contract Sales Reporting. Quarterly Contract Sales Reports must be submitted electronically by the following deadlines for all Contract sales invoiced during the applicable calendar quarter: Quarter For Sales Made In Calendar Quarter Ending Contract Sales Report

  • ANNUAL CONTRACT SALES REPORT Contractor shall provide to Enterprise Services a detailed annual Contract sales report. Such report shall include, at a minimum, the following: ▪ The Goods and/or Services sold (including, as applicable, item number or other identifier); ▪ Per unit quantities sold; ▪ Items and volumes purchased by Purchaser; ▪ Shipment/delivery locations by Purchaser; and ▪ Contract price. This report must be provided in an electronic format that can be read by Microsoft (MS) Excel. Such report is due within thirty (30) calendar days of the annual anniversary of the effective date of this Contract.

  • Contract Services Contract Services mean the services to be delivered by the Contractor, which are so designated in ARTICLE II: HEALTH PLAN PROGRAM STANDARDS of this Agreement.

  • Product Sales Subject to Sections 10.3(c) and 10.3(d), Licensee agrees that it will not sell, offer for sale, or assist third parties (including Affiliates) in selling Product except for the sale and offer for sale of (A) TAF Product, TAF Combination Product, TDF Product and TDF Combination Product for use in the Field and in the countries of the TDF-TAF Territory, (B) COBI Product and COBI Combination Product for use in the Field and in the countries of the COBI Territory, and (C) EVG Product, EVG Combination Product and Quad Product for use in the Field and in the countries of the EVG-Quad Territory.‌ (i) Licensee agrees that during the period in which the Patents are valid and enforceable (on a Product-by-Product basis) it will prohibit its Distributors from selling Product (A) to any other wholesaler or distributor, (B) outside the Territory for which Licensee is licensed for sale of such Product pursuant to Section 2.2, or (C) for any purpose outside the Field. (ii) Licensee agrees that it will not administer the TAF Quad to humans, or sell the TAF Quad until Gilead has obtained marketing approval for the TAF Quad from the FDA. Licensee agrees that it will not administer EVG to humans, or sell Products containing EVG until Gilead has obtained marketing approval for an EVG Product from the FDA. Licensee agrees that it will not administer COBI to humans, or sell Products containing COBI until Gilead has obtained marketing approval for a COBI Product from the FDA. Licensee agrees that it will not administer TAF to humans, or sell Products containing TAF until Gilead has obtained marketing approval for a TAF Product from the FDA. If Gilead obtains marketing approval from the FDA for any Quad Product or a Combination Product containing TAF, COBI or EVG (“Approved Combination Product”) prior to obtaining marketing approval for a TAF Product, EVG Product or COBI Product from the FDA, then Licensee will be allowed to administer such Quad Product or such Approved Combination Product to humans, and sell such Quad Product or such Approved Combination Product from and after the date of such marketing approval from the FDA, but will not (A) administer to humans or sell Combination Products containing EVG other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for an EVG Product, or (B) administer to humans or sell Combination Products containing COBI other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a COBI Product or (C) administer to humans or sell Combination Products containing TAF other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a TAF Product.